IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is the first company to advance genetically modified gamma-delta T cells in to the clinic using our DeltEx Platform, based on ex vivo expanded and activated gamma-delta T cells, our biological expertise, proprietary genetic engineering and cell-type specific manufacturing.

IN8bio is located in New York City with its primary scientific operations in Birmingham, Alabama.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

Press Releases

01 Nov '22
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-founder, will be presenting at two investor

Recent Events